Palbociclib
| Cat. # | Quantity | Price | Lead time | Buy this product |
|---|---|---|---|---|
| 5250-1g | 1 g |
$399.00
|
12 days | |
| 5250-5g | 5 g |
$1296.00
|
12 days |
Palbociclib is a reversible, highly selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). The drug is used exclusively in combination with other agents for the treatment of hormone receptor-positive, HER2-negative advanced-stage breast cancer (depending on the line of therapy, it is combined with letrozole, anastrozole, or fulvestrant). As a first-in-class targeted therapy, it was granted FDA approval on February 3, 2015. Palbociclib is also employed in preclinical and clinical research to evaluate its efficacy against other cancer types and to investigate mechanisms of acquired resistance to targeted therapy.
This product is intended for research use only.
General properties
| Appearance: | yellow solid |
| Molecular weight: | 447.54 |
| CAS number: | 571190-30-2 |
| Molecular formula: | C24H29N7O2 |
| Solubility: | chloroform, DMSO, methanol |
| Quality control: | NMR 1H and HPLC-MS (98+%) |
| Storage conditions: | 24 months after receival at -20°C in the dark. Transportation: at room temperature for up to 3 weeks. Desiccate. |
| MSDS: | Download |
| Product specifications |
For research use only, we do not sell to patients, not for medical use.
Short link - lumiprobe.com/sh/p/hL
The count of items is incorrect.
Your cart is empty
$ 
